Barclays PLC Has $593,000 Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Barclays PLC grew its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 74.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 177,077 shares of the company’s stock after acquiring an additional 75,624 shares during the period. Barclays PLC owned 0.21% of Atea Pharmaceuticals worth $593,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. The Manufacturers Life Insurance Company raised its position in Atea Pharmaceuticals by 14.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,886 shares of the company’s stock valued at $115,000 after purchasing an additional 4,339 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Atea Pharmaceuticals by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,237 shares of the company’s stock worth $54,000 after purchasing an additional 6,343 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Atea Pharmaceuticals in the third quarter valued at $36,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Atea Pharmaceuticals in the third quarter valued at about $37,000. Finally, State Street Corp lifted its position in Atea Pharmaceuticals by 0.7% during the 3rd quarter. State Street Corp now owns 1,733,486 shares of the company’s stock worth $5,807,000 after buying an additional 11,566 shares in the last quarter. 86.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Atea Pharmaceuticals

In other Atea Pharmaceuticals news, Director Franklin M. Berger sold 359,606 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the completion of the sale, the director now directly owns 451,897 shares of the company’s stock, valued at approximately $1,287,906.45. The trade was a 44.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 17.80% of the company’s stock.

Atea Pharmaceuticals Stock Up 0.3 %

Shares of NASDAQ:AVIR opened at $3.33 on Friday. The firm has a market cap of $281.25 million, a P/E ratio of -1.61 and a beta of 0.20. Atea Pharmaceuticals, Inc. has a 12 month low of $2.75 and a 12 month high of $4.60. The company’s 50-day moving average price is $3.26 and its two-hundred day moving average price is $3.46.

Atea Pharmaceuticals (NASDAQ:AVIR) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.13. During the same quarter in the prior year, the firm earned ($0.40) EPS. As a group, equities analysts predict that Atea Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.